ADXN
Addex Therapeutics Ltd
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
4.61
▲ 0.04 (0.88%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
5.63
Prev close
4.57
Day high
6.03
Day low
4.60
Volume
7.22M
Market cap
$6.25M
P/E (TTM)
—
52W range
3.78 – 12.05
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
-16.97%
-15.6%
1M
-16.06%
-19.8%
3M
-29.33%
-32.4%
6M
-31.48%
-42.5%
YTD
-36.01%
-48.3%
1Y
-43.41%
-63.4%
3Y
-53.57%
-127.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$6.25M
Enterprise value$4.08M
Revenue (TTM)$109.50K
Gross profit$-442.22K
EBITDA$-2.69M
Net income$-7.08M
EPS (TTM)$-9.02
Free cash flow$-1.52M
Total cash$935.15K
Total debt$102.27K
Book value / share$4.20
Shares outstanding1.27M
Float808.87K
Short % of float0.38%
Dividend yield—
Beta (5Y)2.00
Short interest
Shares short
4.15K
Prior 1.51K
Change vs prior
+175.2%
Shorts adding
% of float
0.38%
Normal
% of shares out
0.33%
Against total outstanding
Days to cover
2.9
Liquid
Float
808.87K
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Valuation & profitability ratios
Trailing P/E—
Forward P/E-98.80
PEG ratio—
Price / sales—
Price / book1.18
EV / revenue37.25
EV / EBITDA-1.52
Gross margin0.00%
Operating margin-6238.81%
Profit margin0.00%
Return on equity-122.28%
Return on assets-23.59%
Debt / equity3.11
Current ratio0.97
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $29.97K | $404.10K | $1.61M | $1.42M | -92.6% |
| Operating revenue | $29.97K | $404.10K | $1.61M | $1.42M | -92.6% |
| Research & development | $190.19K | $435.19K | $942.71K | $7.88M | -56.3% |
| Selling, general & admin | $1.89M | $1.68M | $2.03M | $3.26M | +12.7% |
| Total operating expense | $2.84M | $3.16M | $3.86M | $11.96M | -10.0% |
| Operating income | -$2.81M | -$2.76M | -$2.24M | -$10.54M | -2.2% |
| Net interest income | -$2.42K | $5.62K | $60.10K | $1.30K | -143.1% |
| Pre-tax income | -$6.84M | -$4.91M | -$2.50M | -$10.80M | -39.4% |
| Tax provision | $0 | $0 | $0 | $0 | — |
| Net income | -$6.73M | $7.06M | -$10.56M | -$20.80M | -195.4% |
| Net income to common | -$6.73M | $7.06M | -$10.56M | -$20.80M | -195.4% |
| Basic EPS | -7.20 | 8.40 | -16.80 | -55.20 | -185.7% |
| Diluted EPS | -7.20 | 8.40 | -16.80 | -55.20 | -185.7% |
| EBIT | -$6.84M | -$4.91M | -$2.50M | -$10.78M | -39.4% |
| EBITDA | -$6.83M | -$4.65M | -$2.19M | -$10.45M | -47.1% |
| Basic shares | 894.76K | 817.61K | 619.23K | 376.54K | +9.4% |
| Diluted shares | 894.76K | 817.61K | 619.23K | 685.30K | +9.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $1.64M | $3.34M | $3.87M | $6.96M | -51.0% |
| Cash & short-term investments | $1.64M | $3.35M | $3.87M | $6.96M | -50.9% |
| Accounts receivable | $20.09K | $15.51K | $110.36K | $416.88K | +29.5% |
| Total current assets | $1.68M | $3.54M | $4.23M | $7.83M | -52.6% |
| Property, plant & equipment | $34.24K | $42.71K | $352.94K | $398.73K | -19.8% |
| Goodwill & intangibles | $0 | $0 | — | — | — |
| Total assets | $6.36M | $10.68M | $4.64M | $8.28M | -40.4% |
| Total current liabilities | $1.20M | $802.09K | $2.89M | $3.28M | +49.5% |
| Total debt | $34.69K | $41.99K | $344.34K | $373.13K | -17.4% |
| Total liabilities | $1.60M | $1.00M | $3.50M | $3.37M | +59.6% |
| Retained earnings | -$360.09M | -$353.36M | -$360.42M | -$349.86M | -1.9% |
| Shareholder equity | $4.77M | $9.68M | $1.15M | $4.91M | -50.7% |
| Working capital | $481.16K | $2.74M | $1.34M | $4.55M | -82.4% |
| Net tangible assets | $4.77M | $9.68M | $1.15M | $4.91M | -50.7% |
| Shares issued | 218.65M | 184.35M | 184.35M | 115.35M | +18.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$6.73M | $7.06M | -$10.56M | -$20.80M | — | -195.4% |
| Depreciation & amortisation | $8.47K | $260.12K | $305.95K | $323.14K | — | -96.7% |
| Stock-based compensation | — | — | — | $3.68M | $1.18M | — |
| Change in working capital | $549.35K | -$1.23M | $213.76K | $157.68K | — | +144.7% |
| Operating cash flow | -$2.17M | -$5.37M | -$7.99M | -$16.44M | — | +59.6% |
| Capital expenditure | — | -$1.27K | -$6.84K | -$581 | -$31.55K | — |
| Investing cash flow | -$680.69K | $4.65M | -$6.84K | $2.97K | — | -114.7% |
| Share buybacks | -$28.85K | -$25.78K | -$48.05K | -$3.49K | — | -11.9% |
| Dividends paid | $0 | $0 | $0 | $0 | — | — |
| Financing cash flow | $1.18M | $104.92K | $5.26M | $3.10M | — | +1,028.4% |
| Free cash flow | -$2.17M | -$5.37M | -$8.00M | -$16.44M | — | +59.6% |
| End cash position | $1.64M | $3.34M | $3.87M | $6.96M | — | -51.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $248 | $29.72K | $0 | $0 | — | -100.0% |
| Operating revenue | $0 | $248 | $29.72K | $0 | $0 | — | -100.0% |
| Research & development | $9.39K | $3.86K | $85.26K | $68.49K | $32.58K | — | +143.4% |
| Selling, general & admin | $389.31K | $567.98K | $459.92K | $411.96K | $448.07K | — | -31.5% |
| Total operating expense | $479.83K | $779.51K | $725.90K | $732.90K | $606.26K | — | -38.4% |
| Operating income | -$479.83K | -$779.26K | -$696.17K | -$732.90K | -$606.26K | — | +38.4% |
| Net interest income | -$956 | -$575 | -$472 | -$826 | -$548 | — | -66.3% |
| Pre-tax income | -$1.71M | -$1.83M | -$1.58M | -$1.96M | -$1.47M | — | +6.6% |
| Tax provision | $0 | — | $0 | $0 | $0 | $0 | — |
| Net income | -$1.71M | -$1.84M | -$1.58M | -$1.84M | -$1.47M | — | +6.8% |
| Net income to common | -$1.71M | -$1.84M | -$1.58M | -$1.84M | -$1.47M | — | +6.8% |
| Basic EPS | -1.20 | — | -1.20 | -2.40 | -1.20 | — | — |
| Diluted EPS | -1.20 | — | -1.20 | -2.40 | -1.20 | — | — |
| EBIT | -$1.71M | -$1.83M | -$1.58M | -$1.96M | -$1.47M | — | +6.7% |
| EBITDA | -$1.70M | -$1.83M | -$1.57M | -$1.96M | -$1.47M | — | +7.1% |
| Basic shares | 987.74K | — | 938.98K | 837.69K | 819.54K | — | — |
| Diluted shares | 987.74K | — | 938.98K | 837.69K | 819.54K | — | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $935.15K | $1.64M | $2.19M | $2.30M | $2.83M | -42.9% |
| Cash & short-term investments | $937.50K | $1.64M | $2.19M | $2.31M | $2.83M | -43.0% |
| Accounts receivable | $31.99K | $20.09K | $51.25K | $38.44K | $35.36K | +59.3% |
| Total current assets | $1.19M | $1.68M | $2.36M | $2.66M | $3.20M | -29.2% |
| Property, plant & equipment | $101.55K | $34.24K | $36.35K | $38.47K | $40.59K | +196.6% |
| Goodwill & intangibles | $0 | $0 | $0 | $0 | $0 | — |
| Total assets | $4.76M | $6.36M | $7.33M | $8.51M | $9.48M | -25.2% |
| Total current liabilities | $1.22M | $1.20M | $1.17M | $1.15M | $1.06M | +1.9% |
| Total debt | $102.27K | $34.69K | $36.55K | $38.39K | $40.20K | +194.8% |
| Total liabilities | $1.47M | $1.60M | $1.37M | $1.29M | $1.19M | -7.8% |
| Retained earnings | -$361.80M | -$360.09M | -$358.25M | -$356.68M | -$354.84M | -0.5% |
| Shareholder equity | $3.29M | $4.77M | $5.96M | $7.21M | $8.30M | -31.0% |
| Working capital | -$32.56K | $481.16K | $1.19M | $1.51M | $2.14M | -106.8% |
| Net tangible assets | $3.29M | $4.77M | $5.96M | $7.21M | $8.30M | -31.0% |
| Shares issued | 218.65M | 218.65M | 184.35M | 184.35M | 184.35M | 0.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$1.71M | -$1.84M | -$1.58M | -$1.84M | -$1.47M | — | +6.8% |
| Depreciation & amortisation | $9.82K | $2.12K | $2.12K | $2.12K | $2.12K | — | +363.6% |
| Change in working capital | -$315.52K | $155.74K | $143.41K | $267.61K | -$17.42K | — | -302.6% |
| Operating cash flow | -$765.84K | -$619.37K | -$533.20K | -$419.84K | -$598.71K | — | -23.6% |
| Investing cash flow | — | -$3.40K | $60.07K | — | — | -$15.90K | — |
| Share buybacks | -$3.18K | -$207 | -$2.75K | -$25.90K | $0 | — | -1,436.7% |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | — | — |
| Financing cash flow | $65.42K | $75.67K | $361.01K | $649.19K | $97.99K | — | -13.5% |
| Free cash flow | -$765.84K | -$619.37K | -$533.20K | -$419.84K | -$598.71K | — | -23.6% |
| End cash position | $935.15K | $1.64M | $2.19M | $2.30M | $2.83M | — | -42.9% |
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders0.00%
Held by institutions0.01%
Institutions holding2
Price targets, consensus spread, insider and institutional ownership.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 31, 24 | HC Wainwright & Co. | UPGRADE | Neutral | Buy |
Moving averages & technicals
SMA 10
5.64
-18.20% from price
SMA 20
5.65
-12.56% from price
SMA 50
5.85
-15.59% from price
SMA 100
6.26
-26.37% from price
SMA 200
6.99
-29.32% from price
EMA 12
5.50
-16.15% from price
EMA 26
5.67
-18.70% from price
EMA 50
5.87
-21.44% from price
RSI (14)
35.0
Neutral
MACD (12,26,9)
-0.17
Hist -0.09
ATR (14)
0.39
7.80% of price
Realised vol 30D
88.6%
Annualised
Bollinger upper
6.39
20, 2σ
Bollinger lower
4.91
20, 2σ
50 / 200 cross
Death
5.85 vs 6.99
Trend bias
Below 200
-29.32%
Risk profile
Beta vs SPY
0.67
Less volatile than market
Correlation to SPY
0.10
Largely independent
Realised vol 30D
88.6%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-58.3%
Peak to trough
Max drawdown 5Y
-97.7%
Peak to trough
ATR 14
0.39
7.80% of price
Beta (reported)
2.00
5Y monthly, from filing
Dividends & splits
Forward rate—
Forward yield—
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:20
Split dateOct 23, 2023
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-07-08
Corporate Changes & Voting Matters
6-K · 2026-06-30
Corporate Changes & Voting Matters
6-K · 2026-06-25
Corporate Changes & Voting Matters
6-K · 2026-06-05
Periodic Financial Reports
20-F · 2026-05-15
Corporate Changes & Voting Matters
6-K · 2026-04-29
Corporate Changes & Voting Matters
6-K · 2026-04-23
Corporate Changes & Voting Matters
6-K · 2026-04-21
Headlines
Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness
GlobeNewswire · 46d ago
Addex Shareholders Approve All Resolutions at Annual General Meeting
GlobeNewswire · 54d ago
Addex Therapeutics Ltd (ADXN) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...
GuruFocus.com · 58d ago
Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewswire · 59d ago
Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026
GlobeNewswire · 62d ago
Addex Convenes Annual General Meeting 2026
GlobeNewswire · 79d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.